Long-term outcomes of anti-CD19 CAR-T in R/R CLL

preview_player
Показать описание
David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the long-term outcomes from a Phase II, randomized dose optimization study of CAR-modified T-cells in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: David L. Porter
  3. Institution: University of Pennsylvania
  4. Event: VJVirtual
  5. Event: SOHO 2020
  6. Format: Interview
Рекомендации по теме
Long-term outcomes of 0:05:22

Long-term outcomes of anti-CD19 CAR-T in R/R CLL

Long-term outcomes of 0:05:25

Long-term outcomes of anti-CD19 CAR-T in R/R CLL

Long-term follow-up results 0:02:00

Long-term follow-up results of the ZUMA-1 trial of anti-CD19 CAR T-cells for non-Hodgkin lymphoma

Anti-CD19 CAR-T for 0:02:41

Anti-CD19 CAR-T for Richter’s transformation: an international multicenter retrospective study

Long-term outcomes with 0:01:31

Long-term outcomes with tafasitamab plus lenalidomide for R/R DLBCL

Engineering T Cells 0:48:50

Engineering T Cells for Cancer - Carl June

Updates in CAR 0:59:27

Updates in CAR T Cell Therapies

Long-term trial supports 0:09:33

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

A summary of 0:03:31

A summary of the prognostic factors that can influence the outcomes of anti-CD19 CAR-T in R/R DLBCL

CD19 CAR T-cells 0:04:47

CD19 CAR T-cells for adults

CD19 CAR T 0:57:03

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience

Real World Outcomes 0:52:39

Real World Outcomes of CAR T Therapy – Experiences from Different Continents

Second CD19-targeted CAR 0:03:23

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

CD19- and CD22-Directed 0:02:36

CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL

Keynote - Cancer 0:58:32

Keynote - Cancer Immunology (Carl H. June)

Long-term Results of 0:01:52

Long-term Results of Zuma-1 Trial for Patients with NHL

CAR T-cell Therapy: 0:59:12

CAR T-cell Therapy: The Good, The Bad and The Long-Term 2022

Second CD19-targeted CAR 0:03:30

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

Longer-term follow-up in 0:01:45

Longer-term follow-up in CAR-T trials

Gut microbiome correlates 0:47:52

Gut microbiome correlates of response and toxicity following anti CD19 CAR T cell therapy

Leveraging Gene Therapy 0:52:12

Leveraging Gene Therapy to Achieve LongTerm Continuous or Controllable Expression of Biotherapeutics

The impact of 0:02:25

The impact of tafasitamab on the efficacy and safety of CD19 CAR-T therapy in preclinical models

An exciting time 0:02:03

An exciting time for CAR T-cell therapy: promising results for B-ALL, nHL and CLL

Evaluating dual-targeting CD19/22 0:03:18

Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL